
- BioPharm International-03-15-2021
- Volume 2021 eBook
- Issue 1
Growing Pipeline of Antisense Oligonucleotides Prompts Guidance
FDA’s newly proposed draft guidance will support IND filings of antisense oligonucleotides, a new class of drugs.
Following decades of research and study, a new class of drug, known as antisense oligonucleotides (ASO), are maturing as drug development efforts advance. In tandem with a growing ASO pipeline, FDA has recently issued a draft guidance, IND Submissions for Individualized Antisense Oligonucleotide Drug Products: Administrative and Procedural Recommendations Guidance for Sponsor-Investigators, for dealing with ASO investigational new drug filings.
Article Details
BioPharm International
eBook: Regulatory Sourcebook, March 2021
March 2021
Pages: 6–10
Citation
When referring to this article, please cite it as F. Mirasol, “Growing Pipeline of Antisense Oligonucleotides Prompts Guidance," BioPharm International Regulatory Sourcebook eBook (March 2021).
Articles in this issue
over 4 years ago
It Takes a Bio/Pharma Villageover 4 years ago
Collaborative Efforts Address Key Data Integrity Challengesover 4 years ago
Can FDA Reinvent Inspections?over 4 years ago
Gene Therapies Target Neurodegenerative Diseasesover 4 years ago
A Real-World Approach to Evaluating Cleanroom Garmentsover 4 years ago
FDA 2021 Guidance Agenda Sees Focus on Genericsover 4 years ago
Regulatory and Standard Setting Organizations DirectoryNewsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.